Overview

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Status:
Recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress the HRAS protein and/or are PIK3CA-mutated and/or PIK3CA-amplified.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Kura Oncology, Inc.

Treatments:

Tipifarnib